Celon Pharma S.A. at BioForum 2018

Maciej Wieczorek, President of Celon Pharma S.A., will take part in this year’s Bioforum 2018, where he will hold a presentation on the novel approach to drug discovery and development process. Bioforum is one of the largest meetings of the biotechnology industry in Poland. This year it will be organised for the 17th time andRead more »

Celon Pharma S.A. significantly increases its net profit in the first quarter of 2018 and improves production and sales efficiency while on its way to conquer other European markets

Over 28 million net revenues from sales of products, goods and materials; PLN 7.5 million of net profit – as compared to approx. PLN 5 million in the first quarter of 2017; A 7% quantitative growth of products sold and strengthening the leading position of most drugs from the portfolio in their respective therapeutic groups.Read more »

Celon Pharma is a business partner of StarShip as part of EIT Health

Celon Pharma representatives are taking part in the StarShip conference which takes place between 7 and 11 of May in Łódz. The purpose of the meeting is to inspire young people from all over Europe to take business and scientific initiatives in the field of Research and Development and in innovative branches of the economy.Read more »

Maciej Wieczorek in Poland Healthcare&Life Sciences Review – an interview

President of the Company, Maciej Wieczorek, about Celon’s business plans and the perspectives of development of the Polish biotech industry in an interview given to Poland Healthcare & Life Sciences Review Pharmaceutical Executive Magazine. We encourage you to read the interview.

Clinical trial of an esketamine-based drug is right on schedule and in accordance with assumptions regarding safety of participants

Celon Pharma S.A. has finalised another part of the phase I clinical trial for its esketamine-based drug. The centre conducting the study confirmed that the course of this part of the trial is in accordance with the assumptions defined in the clinical protocol. Maciej Wieczorek, PhD, President of the Board of Celon Pharma S.A.: Participants receivedRead more »

Celon Pharma S.A. at EIT Health Matchmaking

250 participants: scientists and entrepreneurs, 3 days of debates and meetings on the most important challenges in the area of health and innovation in Europe, including representatives of Celon Pharma. The biggest meeting of this year was aimed at developing the main pillars of the EIT Health agenda in 2018/2019. Jerzy Pieczykolan, PhD, Head ofRead more »

Maciej Wieczorek, at the Impact CEE conference, talking about financing the Polish biotechnology industry and its future

Maciej Wieczorek, CEO was a guest of the Impact CEE conference . A series of such meetings is attended by representatives of national research institutes, Polish and international companies, the public administration and representatives of start-ups. The subject of the first debate was the biotech industry, it took place on 19 February 20118 at theRead more »